# 21 CFR 809.3 Definitions.

21 CFR 809.3 Definitions., “Definitions”, is a CFR section of [21 CFR Part 809, Subpart A—General Provisions](https://ontology.bommaritollc.com/id/01a0f094-b6a2-76a5-ba93-094c055510fb); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f094-cc75-72e7-950c-57db217bf2c2>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f094-b437-7426-9a1d-f0a9f3d3e1aa) › [21 CFR Chapter I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES](https://ontology.bommaritollc.com/id/01a0f094-b455-74b7-9458-ed95d7b5ea58) › [21 CFR Chapter I, Subchapter H—MEDICAL DEVICES](https://ontology.bommaritollc.com/id/01a0f094-b68f-70af-b8e8-5bb30331a2cf) › [21 CFR Part 809—In vitro diagnostic products for human use](https://ontology.bommaritollc.com/id/01a0f094-b894-7577-b5e6-e903d91bd9a5) › [21 CFR Part 809, Subpart A—General Provisions](https://ontology.bommaritollc.com/id/01a0f094-b6a2-76a5-ba93-094c055510fb)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [cfr-section 21 CFR 809.3](https://ontology.bommaritollc.com/id/01a0f094-cc76-745b-bed0-ab2c203d26cc)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/CFR-2025-title21-vol1](https://ontology.bommaritollc.com/id/01a0f094-cc75-72e7-950c-57dab56c6f91)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f094-e4cb-7385-8bd8-df1bbfda7283)
  - [evidence from https://www.govinfo.gov/link/cfr/21/809?sectionnum=3&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f17-6b33-7521-8eeb-30bb52e4d3a2)
- `schema:isPartOf`: [21 CFR Part 809, Subpart A—General Provisions](https://ontology.bommaritollc.com/id/01a0f094-b6a2-76a5-ba93-094c055510fb)
- `schema:legislationIdentifier`: 21 CFR 809.3
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [CFR section](https://ontology.bommaritollc.com/vocab/leg/cfrSection)
- `schema:name`: Definitions
- `schema:url`: [https://www.govinfo.gov/link/cfr/21/809?sectionnum=3&year=mostrecent&link-type=details](https://www.govinfo.gov/link/cfr/21/809?sectionnum=3&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 CFR 809.3 Definitions.

## Elsewhere

- [Official page](https://www.govinfo.gov/link/cfr/21/809?sectionnum=3&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/CFR-2025-title21-vol1) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (4; `eli:cites`):
  - [21 CFR 1271.3 How does FDA define important terms in this part?](https://ontology.bommaritollc.com/id/01a0f094-d5ed-7537-81e7-04b444dd42ab)
  - [21 CFR 801.119 In vitro diagnostic products.](https://ontology.bommaritollc.com/id/01a0f094-cc38-73a5-a161-acacd7dbc81d)
  - [21 U.S.C. 360bbb-4 Countermeasure development, review, and technical assistance](https://ontology.bommaritollc.com/id/01a0f06c-cd43-77c1-8452-5697f21f29ad)
  - [42 U.S.C. 1396d Definitions](https://ontology.bommaritollc.com/id/01a0f07c-e165-7234-abdc-4d9e25f4464e)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f094-cc75-72e7-950c-57db217bf2c2.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f094-cc75-72e7-950c-57db217bf2c2.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f094-cc75-72e7-950c-57db217bf2c2.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f094-cc75-72e7-950c-57db217bf2c2)
Cite as: 21 CFR 809.3 Definitions.. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f094-cc75-72e7-950c-57db217bf2c2
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
